Compare Amylx Pharmaceuticals Inc (AMLX) vs Coursera Inc (COUR) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

Coursera (COUR) trades at $5.71, up 0.71% on the day, with a bearish technical signal but improving fundamentals. Revenue grew to $757.5M in 2025, though net losses persist at -$51M. The Udemy merger and a $500M share repurchase program are key developments. Cash flow from operations remains positive at $108.7M, supporting ongoing investments.

Wall Street analysts are generally optimistic with a $8.00 consensus price target, implying 40% upside. Risks include sustained profitability challenges and integration execution post-merger. The stock presents a growth opportunity if operational synergies materialize, but investors should weigh the high volatility and competitive pressures in edtech.